Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitors (ICI) are now, among other cancers, routinely used for the treatment of advanced or metastatic renal cell carcinoma (mRCC). In mRCC various combinations of ICIs and inhibitors of the vascular epidermal growth factor receptor tyrosine kinase (VEGFR-TKIs) as well as dual c...

Full description

Bibliographic Details
Main Authors: Katharina Leucht, Nalyan Ali, Susan Foller, Marc-Oliver Grimm
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
immune-related adverse events
side effects
immune-checkpoint inhibitors
renal cell carcinoma
immune therapy
adverse reactions
Online Access:https://www.mdpi.com/2072-6694/14/18/4369

Internet

https://www.mdpi.com/2072-6694/14/18/4369

Similar Items